Tectonic Therapeutic (TECX) Stock Price, News & Analysis

Company Overview

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.

Key Stats

• Today's Range: $29.69 to $33.30
• 50-Day Range: $16.06 to $33.02
• 52-Week Range: $12.12 to $33.30
• Volume: 238,711 shs
• Average Volume: 39,291 shs
• Market Capitalization: $1.48 billion
• P/E Ratio: 47.86
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Buy

Tectonic Therapeutic Stock Analysis - MarketRank™

Tectonic Therapeutic scored higher than 76% of companies evaluated by MarketBeat, and ranked 264th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Tectonic Therapeutic has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tectonic Therapeutic has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tectonic Therapeutic are expected to grow in the coming year, from ($4.91) to ($4.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tectonic Therapeutic is 47.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tectonic Therapeutic is 47.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.09.

Price to Book Value per Share Ratio

Tectonic Therapeutic has a P/B Ratio of 15.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of Tectonic Therapeutic has been sold short.

Short Interest Ratio / Days to Cover

Tectonic Therapeutic has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tectonic Therapeutic has recently increased by 166.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tectonic Therapeutic does not currently pay a dividend.

Dividend Growth

Tectonic Therapeutic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.72% of the float of Tectonic Therapeutic has been sold short.

Short Interest Ratio / Days to Cover

Tectonic Therapeutic has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tectonic Therapeutic has recently increased by 166.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.45

News Sentiment

Tectonic Therapeutic has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Tectonic Therapeutic this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Tectonic Therapeutic to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tectonic Therapeutic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,441,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.20% of the stock of Tectonic Therapeutic is held by insiders.

Percentage Held by Institutions

62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TECX Stock Analysis - Frequently Asked Questions

How have TECX shares performed this year?

Tectonic Therapeutic's stock was trading at $16.10 at the start of the year. Since then, TECX shares have increased by 105.1% and is now trading at $33.02.
View the best growth stocks for 2024 here.

How were Tectonic Therapeutic's earnings last quarter?

Tectonic Therapeutic (NASDAQ:TECX) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($3.81) earnings per share for the quarter, missing the consensus estimate of ($1.96) by $1.85.

How do I buy shares of Tectonic Therapeutic?

Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/06/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TECX
• Previous Symbol: NASDAQ:TECX
• CUSIP: N/A
• CIK: 1681087
• Web: www.avrobio.com
• Phone: 617-914-8420
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $76.00
• Low Stock Price Target: $49.00
• Potential Upside/Downside: +81.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.69
• Trailing P/E Ratio: 47.86
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $12.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.05%
• Return on Assets: -37.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.21
• Quick Ratio: 7.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.13 per share
• Price / Book: 15.50

Miscellaneous

• Outstanding Shares: 44,894,000
• Free Float: 40,764,000
• Market Cap: $1.48 billion
• Optionable: N/A
• Beta: 2.63